Pfizer Inc. $PFE Shares Sold by Hourglass Capital LLC

Hourglass Capital LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 438,148 shares of the biopharmaceutical company’s stock after selling 32,390 shares during the quarter. Pfizer comprises about 2.4% of Hourglass Capital LLC’s investment portfolio, making the stock its 8th biggest position. Hourglass Capital LLC’s holdings in Pfizer were worth $10,910,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. KMG Fiduciary Partners LLC raised its stake in Pfizer by 7.5% in the 4th quarter. KMG Fiduciary Partners LLC now owns 142,189 shares of the biopharmaceutical company’s stock valued at $3,541,000 after purchasing an additional 9,941 shares during the last quarter. Accurate Wealth Management LLC grew its holdings in shares of Pfizer by 8.3% during the fourth quarter. Accurate Wealth Management LLC now owns 44,748 shares of the biopharmaceutical company’s stock worth $1,140,000 after buying an additional 3,437 shares in the last quarter. Net Worth Advisory Group purchased a new stake in shares of Pfizer during the fourth quarter worth about $830,000. Dakota Wealth Management raised its position in shares of Pfizer by 4.8% in the fourth quarter. Dakota Wealth Management now owns 364,954 shares of the biopharmaceutical company’s stock valued at $9,087,000 after buying an additional 16,568 shares during the last quarter. Finally, Trust Point Inc. lifted its stake in shares of Pfizer by 3.8% during the fourth quarter. Trust Point Inc. now owns 32,412 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 1,174 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $27.03 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The firm has a market capitalization of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47. The business’s 50-day simple moving average is $26.84 and its 200-day simple moving average is $25.68.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the company earned $0.63 EPS. The company’s revenue was down 1.2% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Morgan Stanley set a $27.00 price target on Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Royal Bank Of Canada began coverage on Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.